Press release
Industry and Government Bodies Gather for Crucial Updates into Antibiotic Resistance in Just 3 Weeks at Superbugs USA 2016
Just 3 weeks remain until SMi Group open its doors to host Superbugs & Superdrugs USA, the American installment of its long running European conference.Following on from 18 years of expertise in pushing industry collaboration and knowledge to promote antibiotic drug discovery, the Superbugs & Superdrugs event will travel across the Atlantic for the first time to gather an audience of senior industry experts and leading government bodies to tackle the critical threat of antibiotic resistance.
Featured speakers include:
Dr Pilar Ramon-Pardo, Advisor on Clinical Management of Infectious Diseases and Antimicrobial Resistance, PAHO/WHO
Dr Christopher Houchens, Branch Chief, Antibacterials Program, BARDA
Dr Rosemarie Aurigemma, Chief, Biodefense Drug Development Section, DMID, NIAID, NIH
Dr John Rex, Senior Vice President and Chief Strategy Officer, Infection Business Unit, AstraZeneca
Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, Pfizer
Dr Anthony Simon Lynch, Senior Scientific Director, Janssen Research & Development LLC
Dr Mahesh Kumar, Vice President, Global Biological Research and Development, Zoetis
David Cook, Chief Scientific Officer , Blueberry Therapeutics Ltd
5 agenda highlights will consist of:
1 .HOST NATION KEYNOTES: The agenda will evaluate current progress in the development of the US National Action Plan through host nation keynotes presented by leading government bodies including PAHO/WHO, NIH and BARDA. Highlights include updates into PPP investment opportunities and results following the first of year of the US Government “CARB Initiative”.
Christopher Houchens, Branch Chief of BARDA’s Antibacterials Program, said:
"BARDA and its interagency partners, specifically the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Disease (NIAID) in particular, have demonstrated success in providing direct support to developers of promising products capable of addressing the global threat of AMR that may have otherwise never been developed without support."
2. TALKS ON DRUG DISCOVERY: Attendees will be encouraged to develop clinical assets through strategic partnerships and will receive progressive insight on innovative developments in big pharma. Topics will include the discovery of new pathways, the microbial metagenomics approach, and zoonotic links between animals and humans to target emerging infectious diseases.
Dr Anthony Simon Lynch, Senior Scientific Director from Janssen Research & Development LLC commented:
"Sessions focused on novel platforms and agents in the treatment and prevention of diseases caused by so-called ‘Superbugs’ are all of interest as they cover a broad spectrum of alternate approaches and it’s always good to be cognizant of new science and potential opportunities."
Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines from Pfizer said:
"Pfizer believes that a mix of economic incentives, coupled with regulatory reforms specifically focused on antibiotics and vaccines for drug resistant strains and emerging infectious diseases, can successfully incentivize new R&D."
3. DIRECTION ON STRENGTHENING THE ANTIBIOTIC PIPELINE: The program will include presentations on restoring antibiotic sensitivity in multi-drug resistance infections with talks on targeting mechanisms, novel approaches in treating gram-negative infections, combination therapy, and protein based biologics as adjuncts to existing therapies.
David Cook, Chief Scientific Officer from Blueberry Therapeutics, singled out this session as being one of particular interest:
"I’m looking forward to the section on “Strengthening the Pipeline” and hearing about the other work going on in developing beta-lactamase inhibitors."
4. A LOOK AT ANIMAL MODELS: The first of two interactive workshops will be hosted by the UNT Health Science Centre and will offer in-depth discussions on animal models in antibiotic drug discovery. The session will cover topics on regulation, proof of concept studies and analyse supportive data.
5. REGULATORY GUIDANCE: The second workshop will determine PK/PD targets for optimising dosage requirements for new antibacterials with regulatory recommendations from the National Institute of Allergy & Infectious Diseases (NIAID) .
Further information including a detailed program and full speaker line-up is available online. Registration to attend can be made at superbugs-usa.com/openpr
A series of interviews with keynote speakers is also available to read in the event download centre at http://www.smi-online.co.uk/2016superbugsusa.asp#tab_downloads
Superbugs & Superdrugs USA 2016
Conference: Nov 14 – 15
Interactive workshops: Nov 16
Renaissance Woodbridge Hotel, Iselin, New Jersey
Contact Information:
For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit http://www.superbugs-usa.com/openpr or contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
1 Westminster Bridge Rd, London SE1 7XW
Phone: 020 7827 6000
For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Industry and Government Bodies Gather for Crucial Updates into Antibiotic Resistance in Just 3 Weeks at Superbugs USA 2016 here
News-ID: 376400 • Views: …
More Releases from SMi Group
![Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference](https://cdn.open-pr.com/V/4/V413680587_g.jpg)
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the…
![Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.](https://cdn.open-pr.com/V/4/V411437700_g.jpg)
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK.
With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading…
![FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA](https://cdn.open-pr.com/V/4/V406661861_g.jpg)
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022.
With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and…
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week.
With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman.
The…
More Releases for Superbugs
Interview with Martin Everett speaker at SMi's Superbugs & Superdrugs Conference
SMi Reports: An Interview with Martin Everett, Chief Scientific Officer, at Antabio, who will be speaking at SMi's highly anticipated 22nd Annual Superbugs & Superdrugs Conference on the 30th and 31st March 2020 in London.
This year's global focused two-day conference pharmaceutical is for industry professionals looking to gain an in-depth knowledge of the scientific, economic, and regulatory challenges facing the critical global issue of antibiotic resistance.
For interested individuals to attend…
Evotec & Scynexis to lead the workshops for Superbugs & Superdrugs 2020
SMi Reports: Interactive workshop overview for SMi's 22nd Annual Superbugs & Superdrugs Conference, London in March 2020
SMi’s highly anticipated 22nd Annual Superbugs & Superdrugs Conference will commence on the 30th and 31st March 2020 and in London, UK.
For this year’s conference, industry leaders and key profiles from leading pharmaceutical organisations will be brought together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding…
SMi’s 22nd Annual Superbugs & Superdrugs Conference 2020 – Speakers Announce …
SMi Reports: the agenda and speaker overview of the upcoming SMi’s 22nd Annual Superbugs & Superdrugs Conference 2020, in London is now available to view.
SMi Group is delighted to announce the return of the successful Superbugs & Superdrugs Conference for its 22nd year, taking place on 30th and 31st March 2020 at the Holiday Inn Kensington Forum in London. Antibiotics have long been one of the most important pharmaceuticals…
Four weeks until SMi’s 21st Annual Superbugs & Superdrugs Conference 2019
SMi Reports: Senior industry experts will gather in London to discuss the recent advances made in combating antibiotic resistance.
As the global threat of antimicrobial resistance continues to grow, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections.
For this reason, the Superbugs & Superdrugs conference, taking…
Registration Officially Opens for the 21st Annual Superbugs & Superdrugs Confere …
As the global threat of antimicrobial resistance continues to grow, the advances of modern medicine are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections.
SMi’s highly anticipated Superbugs & Superdrugs conference is set to return to London, UK for its 21st year running, on the 18th & 19th March 2019 (http://www.superbugssuperdrugs.com/openpr). This…
Superbugs & Superdrugs USA Conference returns to New Jersey this November
SMi Group reports: agenda released for 3rd annual Superbugs & Superdrugs USA conference
Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group is pleased to announce the release of the official agenda for the 3rd annual Superbugs & Superdrugs USA Conference, which is due to take place in Iselin, New Jersey on November 12 - 13, 2018.
Antimicrobial resistance, leading to the…